會議基本信息：
會議名稱： 第五屆ADC藥物開發(fā)峰會
會議地點： 蘇州，中國
會議時間： 2024年3月1-2日

會議背景
截止到2023年10月，全世界范圍內共有15款ADC藥物獲批上市。尤其是從2018年至今，在科研單位及行業(yè)的努力下，ADC藥物的臨床療效取得了重大進展，以Enhertu為代表的ADC逐漸顯示出成為10億美元重磅炸彈的藥品趨勢，年復合增長率已經達到了40.4%。創(chuàng)新的偶聯(lián)技術平臺，優(yōu)化的DARs值，改進的linker可以進一步的控制ADC的精準性、臨床療效、以及減少毒素副作用。在此背景下，中國的ADC藥物開發(fā)也成功的吸引了全世界的目標，投資，授權合作不斷。為此，我們將于2024年3月1-2日在蘇州，召開第五屆ADC藥物開發(fā)峰會。期待大家的出席！

會議主題：
M（主論壇）. 全球ADC市場動態(tài)：投資與合作趨勢
ADC藥物開發(fā)走進舞臺中央
中國ADC藥物合作開發(fā)，國際大藥廠押注下一個重磅炸彈賽道
ADC兼并，收購，合作的背后驅動力
A1. 靶點發(fā)現(xiàn)、轉化醫(yī)學及臨床前開發(fā)
創(chuàng)新靶點及生物標志物驗證
ADC非臨床研究要點：藥理學、毒理學、安全性評價要點
監(jiān)管視角：ADC非臨床開發(fā)挑戰(zhàn)
可驗證的端到端的ADC藥物發(fā)現(xiàn)平臺
避免熱點靶點內卷、ADC開發(fā)的熱門方向
A2: 臨床開發(fā)：全球化及腫瘤以外適應癥探索
全球化多中心臨床的開發(fā)挑戰(zhàn)
差異化臨床開發(fā): 臨床策略提升ADC成功率
ADC聯(lián)合治療方向：與化療Combo，
超越腫瘤及血液瘤：ADC實體瘤進展與非腫瘤適應癥開發(fā)
簡化臨床開發(fā)，加速推動候選分子從實驗室邁向臨床
A3: 下一代創(chuàng)新偶聯(lián)治療實體
新型作用機制下的新型有效負載：超越傳統(tǒng)毒素
不斷創(chuàng)新的新型偶聯(lián)治療實體
推動XDC進入臨床：創(chuàng)新設計以及控制開發(fā)風險
創(chuàng)新偶聯(lián)治療實體分享：蛋白降解偶聯(lián) / 多肽偶聯(lián) / 雙抗偶聯(lián) / 雙環(huán)肽的放射性偶聯(lián) 等等
B1: 攜手共進：MNC & 本土Biotech合作
ADC藥物更廣泛的治療窗口挑戰(zhàn)
MNC與中國本土創(chuàng)新Biotech管線合作開發(fā)，開發(fā)進展協(xié)同挑戰(zhàn)
全球ADC藥物開發(fā)背景下的中國機會
下一步合作趨勢：擴大適應癥以及推進到一二線治療
出海授權合作中的風險控制、知識產權保護
資本視角：ADC藥物投資方向
B2: 案例展示：創(chuàng)新ADC技術平臺
全面革新ADC 設計：優(yōu)化的抗體、可裂解的連接子、創(chuàng)新的毒素
設計鏈接器以增加ADC 功效和降低毒性
使用兩種不同的雙有效負載 ADC
細胞毒素可降低藥物耐藥性
新型ADC平臺：負載多樣化
B3: 授權出海及商業(yè)化策略
從PD-1授權出海中學到的經驗與啟示
建立更廣泛的合作來擴展管線以及開拓海外市場
與海外監(jiān)管單位保持密切溝通，攜手合作方共同應對注冊申報挑戰(zhàn)
急劇增長的ADC銷售份額共同應對海外市場商業(yè)化開發(fā)挑戰(zhàn)
C1: 連接子 & 毒素 以及ADC的耐受性
通過接頭設計: 提高功效、穩(wěn)定性并減少脫靶毒性
非內化的ADC開發(fā)
ADC 毒性的影響和優(yōu)化策略
最小化毒性并提高耐受性, 以最大化 ADC 的治療效果
免疫原性、旁觀者效應或系統(tǒng)性毒素以及快速清除
C2: 選擇可靠的合作伙伴共同應對工藝挑戰(zhàn)
確保ADC的產品質量、效力
穩(wěn)健可放大的工藝、支持快速工藝轉移
如何協(xié)同小分子與大分子共同工藝優(yōu)化的挑戰(zhàn)
抗體工程化、藥物遞送策略
應對不同偶聯(lián)ADC的下游高效純化
全球ADC外包市場、如何選擇可靠的CDMO合作伙伴
C3; 質量控制及生物分析策略
識別和研究新型偶聯(lián)位點的快速表征分析
推動CQA屬性落地，迎接生產挑戰(zhàn)
解決ADC藥物特殊的生物分析挑戰(zhàn)
復雜的結構對生物分析的影響
與時俱進的生物分析工具
ADC藥物的質量控制和藥代PK分析策略

中文官網(wǎng)：https://www.bagevent.com/event/adc2024
 
合作聯(lián)系：
演講聯(lián)系人：Ada   18601610075   [email protected]
贊助聯(lián)系人：Wilson  18662147488  [email protected]
 
 
EN Version

Event info:
Name：The 5th ADC Development Summit (China Focus)
Location： Suzhou，China
Time： March 1-2，2024

Event Background:
As of October 30,2023, 15 ADC drugs had received approval worldwide.  Promising clinical benefits and significant advancements had been made by the effort from academic and industry since 2018.  For instance, Enhertu a groundbreaking treatment for HER2+ Cancer showing great potential to become blockbuster. The global ADC market in 2022 has grown to US$7.9 billion with a CAGR of 40.4% between 2018 and 2022. Innovation Conjugate platform, optimization of DASs and improved linker together improving ADC precision、clinical efficiency、reduced off-target toxicity。 China's ADC drug development has also successfully attracted investments, cooperation, and licensing out for big pharmaceuticals worldwide.  As for this background, we are going to launch the 5th ADC Development Summit in March 1-2, 2024. Suzhou, China.  We are looking forward to meeting you onsite!
  
Event Topics
Main Forum - Global ADC Investment and Cooperation
ADCs Taking Center Stage
Chinese Collaborations, Approvals and Expansions
The Drivers Behind the Demand for ADCs
A1: Target Selection and Preclinical Research
Novel Biomarkers in ADC
ADC Nonclinical Pharmacology, Toxicology Research and Safety Considerations
Regulatory Perspective of ADC，Nonclinical Safety Assessments
Validated, End-to-End ADC Discovery Platform
Evolving Strategies for Target Selection for ADC
A2: Clinical Development and Beyond Oncology
Global Clinical Trials Challenge
The Strategic Significance and Practice of Clinical Differentiation Development of ADC
ADC Combination Therapy: Combining with Chemotherapy
Exploring ADCs in Solid Tumor and Beyond Streamline the Clinical Path
A3: Next-Generation Conjugates Modalities
Emerging Different Types of Payloads with Novel Mechanism
Increasing Investment for XDC
Better Design and Bring XDC into Clinical
Emerging New Modality ：Degrader-Antibody Conjugates / Peptide Drug Conjugates / Dual-Site or Dual-Target ADCs / Bicycle Radio-Conjugates etc…
B1: Collaboration Between MNC & China Biotech
Wider Therapeutic Window Challenge
Development Progress and Collaborative Challenges Between MNC and Chinese Biotech
Global ADC Drug Development & China Opportunities
Next Cooperation Trend: Expansion of Applications and Treatment lines
Risk Management and Patent Protection
B2: Novel ADC Platform Showcase
Revolutionizing ADC Design: Optimized Antibodies, Cleavable Linkers, Innovative Payloads
Designing Linkers to Increase ADC Efficacy and Reduce Toxicity
Dual-Payload ADCs Using Two Different Cytotoxins to Reduce Resistance
Novel ADC Platform： Payload Diversification
B3: License-out & Commercialization Strategy
Lessons Learned from PD-1 License-Out
Broad Collaborations to Expand Pipelines and Explore Overseas Opportunities
Together With Partner and Communicate with Regulatory Closely for IND Application
Jointly Respond to the Commercial Development of Overseas Markets
C1: Linker & Toxicities and ADC Tolerability
Improve Efficacy, Stability, and Reduce Off-Target Toxicities with Linker Design
Effects of ADC Toxicity and Optimization Strategies
Minimizing Toxicities & Improving Tolerability to Maximize the Tl of ADCs
Immunogenicity, Bystander or Systemic Toxicity, and Rapid Clearance
C2: Process Development with Reliable Partner
Ensuring Your ADC's Product Quality, Identity & Potency
Optimizing ADC Process Development to Deliver on Accelerated Timelines
Engineering, Delivery & Dosing Strategies
Diversification of ADC Formats and Overcoming Purification Challenges
C3: Quality Control and Bioanalytical Strategies
Bioanalytical Strategies for ADC PK Analysis
Rapid Characterization Methods to Identify and Investigate New Bioconjugation Sites
Manufacturing Challenges and Trends
Solving Unique ADC Bioanalytical Challenges State-of-the-art Bioanalytical Tools

Event Website: https://www.bagevent.com/event/ADC2024EN

Contact Us
Speak Opportunity：Ada   18601610075   [email protected]
Sponsor Opportunity：Wilson  18662147488  [email protected]